Metformin Nevik

Metformin Hydrochloride, the active ingredient in Metformin Nevik, is a biguanide presented as an oral dosage form for oral use. It is employed to improve glycemic control in adults with type 2 diabetes mellitus. By decreasing hepatic glucose output and enhancing peripheral insulin sensitivity, it helps lower blood glucose levels as part of a comprehensive diabetes management plan.

GNH USA supplies Metformin Nevik as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, pharmacies and clinics worldwide.

Metformin Nevik is a biguanide that acts on glucose metabolism to manage hyperglycaemia. - Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes when combined with lifestyle measures. - Gestational diabetes mellitus: may be used when diet alone does not achieve target glucose levels, under specialist supervision.

Metformin Nevik may be associated with a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Metallic taste in the mouth. - Decreased appetite. - Mild headache. - Weight loss or reduced body mass index.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal metabolic disturbance. - Severe hypoglycaemia (usually when combined with other glucose‑lowering agents). - Hepatotoxicity: elevated liver enzymes. - Skin reactions: rash or pruritus. - Vitamin B12 deficiency with long‑term use.

Metformin Nevik requires careful use in several clinical situations. - Renal function assessment: avoid or adjust dose in patients with impaired renal clearance. - Hepatic disease: monitor liver function before and during therapy. - Cardiovascular status: use cautiously in patients with unstable heart failure. - Alcohol consumption: limit intake to reduce risk of lactic acidosis. - Pregnancy and lactation: evaluate risk‑benefit ratio with a healthcare professional. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Metformin Nevik can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Certain antiretrovirals (e.g., didanosine): increase risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics (loop or thiazide): can affect renal function and metformin clearance. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Oral corticosteroids: may raise blood glucose, requiring dose adjustment. - Thyroid hormones: may influence glucose metabolism, necessitating monitoring.